US Bancorp DE Trims Stock Position in Chemed Co. (NYSE:CHE)

US Bancorp DE trimmed its holdings in Chemed Co. (NYSE:CHE) by 1.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,052 shares of the company’s stock after selling 72 shares during the quarter. US Bancorp DE’s holdings in Chemed were worth $2,435,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Chemed in the 1st quarter valued at about $1,064,000. ProShare Advisors LLC raised its position in Chemed by 6,288.9% during the first quarter. ProShare Advisors LLC now owns 50,600 shares of the company’s stock valued at $32,482,000 after acquiring an additional 49,808 shares in the last quarter. Sei Investments Co. lifted its holdings in Chemed by 4.5% in the first quarter. Sei Investments Co. now owns 41,336 shares of the company’s stock valued at $26,535,000 after acquiring an additional 1,780 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in Chemed in the 1st quarter worth approximately $4,512,000. Finally, Quantbot Technologies LP grew its stake in shares of Chemed by 167.3% during the 1st quarter. Quantbot Technologies LP now owns 2,999 shares of the company’s stock worth $1,925,000 after purchasing an additional 1,877 shares during the period. 95.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada decreased their target price on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a research note on Tuesday.

Chemed Stock Up 1.6 %

Shares of Chemed stock opened at $533.17 on Wednesday. The firm has a market cap of $8.02 billion, a PE ratio of 26.94, a P/E/G ratio of 2.16 and a beta of 0.46. Chemed Co. has a twelve month low of $523.33 and a twelve month high of $654.62. The business has a 50-day moving average price of $583.68 and a 200 day moving average price of $566.74.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. During the same period in the previous year, the company earned $5.32 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. On average, sell-side analysts expect that Chemed Co. will post 22.41 EPS for the current year.

Insider Activity

In related news, Director George J. Walsh III sold 200 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $577.95, for a total transaction of $115,590.00. Following the completion of the transaction, the director now owns 3,446 shares in the company, valued at $1,991,615.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director George J. Walsh III sold 200 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $577.95, for a total value of $115,590.00. Following the completion of the transaction, the director now directly owns 3,446 shares of the company’s stock, valued at approximately $1,991,615.70. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrea R. Lindell sold 831 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $571.51, for a total value of $474,924.81. Following the completion of the transaction, the director now owns 5,725 shares in the company, valued at $3,271,894.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,144 shares of company stock worth $3,002,419 over the last 90 days. 3.32% of the stock is currently owned by company insiders.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.